CRISPR And The Continuing Quest For CAR-T Safety And Durability

CAR-T is an immunotherapy that is currently used to treat blood cancers and is in clinical trials to treat other cancers as well. Because the first-generation CAR-T therapies are autologous – based on cells from the patient the therapy is intended for – these therapies are limited by the cost, time and infrastructure required to handle each person’s cells. In this blog, explore the evolution of an allogeneic CAR-T program, which could result in a large batch of “universal” therapy based on donor cells as opposed to a customized batch for an individual patient.